| Literature DB >> 31718071 |
Lu Liu1, Lei Zhang1, Ze-Xu Cui1, Xiao-Yan Liu1, Wei Xu1, Xiu-Wei Yang1.
Abstract
Psoralen (P) and isopsoralen (IP) are the main active ingredients in the dried fruit of Psoralen corylifolia L. (PC), with a wide range of pharmacology activities. The intestinal bacteria biotransformation plays a central role in the metabolism of the complex ingredients in traditional Chinese medicine (TCM). Our study aimed to investigated the metabolic profile of P and IP in the intestinal condition, co-cultured with human fecal bacteria anaerobically. Four bio-transforming products were obtained, including 6,7-furano-hydrocoumaric acid (P-1) and 6,7-furano-hydro- coumaric acid methyl ester (P-2), which transformed from P, and 5,6-furano-hydrocoumaric acid (IP-1) and 5,6-furano-hydrocoumaric acid methyl ester (IP-2), which were transformed from IP. It is worth mentioning that IP-2 is a new compound that has not been published. Their structures were analyzed based on their spectroscopic data. Moreover, a highly sensitive ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was used to characterize the metabolic pathways of P, IP, and their bio-transforming products in the reaction samples. In addition, the dampening effects against the oxidative stress of P, IP, and their bio-transforming products by human intestinal flora were estimated in vitro via the human colorectal cells (HCT116) and heterogeneous human epithelial colorectal adenocarcinoma cells (Caco-2) cell lines. The results showed that the metabolites have stronger activity than P and IP, which possibly provides a basis for elucidating the treating mechanisms of PC extract against inflammatory bowel disease.Entities:
Keywords: LC-MS/MS; Psoralea corylifolia L.; human intestinal flora; isopsoralen; oxidative stress; psoralen
Mesh:
Substances:
Year: 2019 PMID: 31718071 PMCID: PMC6891621 DOI: 10.3390/molecules24224080
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures and MS/MS fragmentation patterns of psoralen (P), isopsoralen (IP), and their transformation products.
Figure 2The possible metabolic pathways of P and IP by human intestinal bacteria.
Optimized multiple reaction monitoring (MRM) parameters of five compounds and internal standard (I.S.) in mass detection.
| Analyte | MRM | Precursor Ion–Product Ion ( | Q1 Pre-Bias * (V) | Collision Energy (V) | Q3 Pre-Bias * (V) | Dwell Time (msec) | Retention Time (min) |
|---|---|---|---|---|---|---|---|
| P | MRM (+) | 187.10–131.05 | −14.0 | −27.0 | −23.0 | 100.0 | 3.351 |
| P-1 | MRM (−) | 205.15–161.15 | 23.0 | 16.0 | 16.0 | 100.0 | 0.768 |
| P-2 | MRM (−) | 219.15–187.10 | 16.0 | 11.0 | 18.0 | 100.0 | 3.873 |
| IP | MRM (+) | 187.00–131.95 | −14.0 | −23.0 | −22.0 | 100.0 | 3.421 |
| IP-1 | MRM (−) | 205.10–146.15 | 15.0 | 22.0 | 28.0 | 100.0 | 0.842 |
| IP-2 | MRM (−) | 219.15–187.15 | 16.0 | 12.0 | 19.0 | 100.0 | 4.030 |
| I.S. | MRM (+) | 271.05–147.05 | −30.0 | −29.0 | −27.0 | 44.0 | 6.245 |
*: Q1 pre-bias and Q3 pre-bias: voltage enhance the ion transmission of the precursor ion and the product ion; dwell time: residence time during an acquisition point.
Figure 3The typical MRM chromatograms with different disposal manners; (A) blank bacterial suspension; (B) blank bacterial suspension spiked with the six analytes and I.S. (LQC); (C) the chromatograms of the six components and I.S. in an active bacterial suspension, which were obtained at 12 h.
The regression data, lower limit of quantitations (LLOQs), and lower limits of detections (LLODs) of six compounds in human intestinal flora.
| Analytes | Regression Equation |
| Linear Range * | LLOQ * | LLOD * |
|---|---|---|---|---|---|
| P | y = 46.4226x + 198.909 | 0.9977 | 4.88–2440 | 4.88 | 2.44 |
| P-1 | y = 318.924x + 316.47 | 0.9921 | 5.30–2650 | 5.30 | 2.65 |
| P-2 | y = 48.9102x + 1577.72 | 0.9931 | 2.02–1010 | 2.02 | 1.01 |
| IP | y = 227.105x − 2813.5 | 0.9939 | 5.06–2530 | 5.06 | 2.53 |
| IP-1 | y = 226.079x − 1952.0 | 0.9906 | 4.46–2230 | 4.46 | 2.23 |
| IP-2 | y = 854.015x − 2543.2 | 0.9957 | 2.14–1070 | 2.14 | 1.07 |
*: The linear range, LLOQ and LLOD units of compounds in human intestinal flora are ng/mL.
Precision and accuracy of the determination of six compounds in the human intestinal flora (n = 18, six replicates per day for three days).
| Compounds | Spiked Concentration (ng/mL) | Measured Concentration (ng/mL) | Accuracy (%) | Precision (%) | |
|---|---|---|---|---|---|
| Intra-Day | Inter-Day | ||||
| P | 4.880 | 4.80 ± 0.50 | −1.40 | 4.80 | 9.50 |
| 12.20 | 13.22 ± 1.70 | 8.39 | 12.72 | 13.69 | |
| 610.0 | 611.0 ± 75.17 | 0.16 | 13.05 | 3.04 | |
| 1952 | 2067 ± 144.0 | 5.89 | 7.14 | 5.47 | |
| P-1 | 5.300 | 5.140 ± 0.330 | −3.00 | 7.80 | 5.20 |
| 13.25 | 13.07 ± 1.530 | −1.36 | 12.35 | 3.63 | |
| 662.5 | 594.5 ± 60.34 | −10.26 | 10.11 | 10.45 | |
| 2120 | 2204 ± 203.0 | 3.96 | 9.19 | 9.38 | |
| P-2 | 2.020 | 2.240 ± 0.156 | 10.80 | 3.50 | 6.30 |
| 5.050 | 5.680 ± 0.590 | 12.43 | 10.56 | 9.82 | |
| 252.5 | 250.8 ± 29.33 | −0.69 | 12.00 | 9.08 | |
| 808.0 | 847.3 ± 34.10 | 4.86 | 4.25 | 1.54 | |
| IP | 5.060 | 5.140 ± 0.321 | 1.60 | 4.40 | 5.60 |
| 12.65 | 12.65 ± 0.460 | 0.12 | 3.23 | 5.99 | |
| 632.5 | 556.7 ± 63.88 | −0.14 | 11.54 | 10.96 | |
| 2024 | 1794 ± 110.1 | 0.57 | 8.45 | 2.78 | |
| IP-1 | 4.460 | 4.471 ± 0.407 | 8.20 | 9.60 | 7.00 |
| 11.15 | 12.36 ± 1.041 | −2.12 | 8.00 | 11.10 | |
| 557.5 | 528.0 ± 45.88 | −5.30 | 8.65 | 9.01 | |
| 1784 | 1820 ± 86.62.3 | 2.02 | 6.49 | 7.85 | |
| IP-2 | 2.140 | 2.401 ± 0.321 | 12.20 | 9.20 | 11.80 |
| 5.350 | 5.030 ± 0.430 | −5.90 | 8.81 | 4.86 | |
| 267.5 | 242.2 ± 25.68 | −7.75 | 10.93 | 7.79 | |
| 856.0 | 839.2 ± 65.35 | −2.02 | 9.29 | 13.04 | |
Matrix effects and extraction recovery for the analytes in human intestinal flora (n = 6).
| Compounds | Spiked Concentration (ng/mL) | Matrix Effect | Extraction Recovery | ||
|---|---|---|---|---|---|
| Mean (%) | RSD (%) | Mean (%) | RSD (%) | ||
|
| 12.20 | 86.87 | 5.68 | 98.24 | 12.54 |
| 610.0 | 88.37 | 7.94 | 95.99 | 5.57 | |
| 1952 | 98.49 | 11.52 | 91.86 | 5.12 | |
| P-1 | 13.25 | 89.77 | 3.54 | 85.82 | 8.49 |
| 662.5 | 101.14 | 9.56 | 94.81 | 4.10 | |
| 2120 | 99.26 | 10.55 | 89.49 | 13.53 | |
| P-2 | 5.05 | 110.48 | 10.38 | 97.17 | 6.51 |
| 252.5 | 96.99 | 4.52 | 96.02 | 4.84 | |
| 808 | 86.87 | 4.77 | 90.48 | 6.39 | |
| IP | 12.63 | 91.15 | 10.80 | 95.39 | 4.67 |
| 632.5 | 95.51 | 3.37 | 91.31 | 4.72 | |
| 2024 | 92.37 | 4.18 | 89.94 | 2.75 | |
| IP-1 | 11.15 | 94.00 | 7.38 | 89.65 | 3.87 |
| 557.5 | 93.53 | 7.86 | 87.95 | 9.78 | |
| 1784 | 98.19 | 8.75 | 82.04 | 8.58 | |
| IP-2 | 5.35 | 98.55 | 11.08 | 97.28 | 13.34 |
| 267.5 | 95.74 | 14.34 | 85.71 | 12.70 | |
| 856.0 | 83.88 | 14.10 | 94.07 | 14.67 | |
Figure 4The time course of biotransformation of P (A) and IP (B) by active human intestinal flora (n = 3, mean ± standard deviation (SD).
Figure 5Cytotoxicity ((a) for HCT116 cell line; (b) for Caco-2 cell line) and the protect effects against H2O2-induced oxidative damage ((A) for HCT116 cell line; (B) for Caco-2 cell line) of P, IP, and their transformation products. The Cur group was the positive control group. Data are shown as the mean ± SD (n = 3). ▲▲▲ p < 0.001 vs control group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs the H2O2 group.
Figure 6The cell viability of different cell lines against the H2O2 concentration ((A): human colorectal cells (HCT116); (B): heterogeneous human epithelial colorectal adenocarcinoma cells (Caco-2)).